Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases worldwide.
Gilead’s operation in Amsterdam is responsible for medical, sales and marketing support for our products throughout the Netherlands.
Member drugs development companies Nefarma publish their annual research and development costs in the Netherlands on their website by 01 July. Such research and development costs are published in other European countries as well. Drugs development companies spend on average 15% of their total revenue on research and development. There are relatively few research and development activities In the Netherlands, mainly related to international level.
To make research and development costs as transparent as possible, EFPIA (European Federation of Pharmaceutical Industries and Associations) asked all member pharmaceutical companies to publish their research and development costs on their own websites (click here for “Disclosure Codes make the cost of research and development as transparent as possible: EFPIA has asked all affiliated drug manufacturers in Europe to publish these amounts on their company website from 2016” (click here for the EFPIA Disclosure Code)). The research and development costs include spend on non-clinical studies, clinical trials and prospective non-intervention studies. These costs are published annually in aggregate by each member company at a national level.
The amount paid in 2017 is € 1.221.682,94
Relationships with Patient Organizations
Gilead Sciences provided support to patient organisations via sponsorship agreements or unrestricted grants.
The information over 2017 regarding the financial support of Gilead Sciences to patient organisations can be found in the Transparency Register (
For a listing of previous years’ support, click here.
This page is intended for visitors outside of the United States.